Published in Blood Weekly, November 24th, 2005
The Directors of MicroCor, a subsidiary of InMedica, have accepted the prototype as complying with the condition of phase I of the Joint Development Agreement between the companies and have agreed to issue 500,000 new shares of MicroCor common stock to Wescor in consideration for their work on this phase of the project.
Wescor has started work on phase II of the project, which includes engineering testing, production of additional prototypes, as well as clinical trials, as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.